Measles neutralising antibody levels in patients receiving intravenous immunoglobulin treatment - a sub-analysis of a randomized, cross-over bioequivalence trial.
<h4>Background</h4>Intravenous immunoglobulin is a replacement therapy for patients living with primary immunodeficiencies. Each batch of intravenous immunoglobulin is required by the Food and Drug Administration to contain threshold levels of measles neutralising antibodies. Widespread...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2025-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0316926 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|